Docetaxel and SX-682 for Head and Neck or Prostate Cancer
This study is testing a combination of two drugs, SX-682 and docetaxel (DTX), for people with head and neck cancer or prostate cancer that has returned or spread. Docetaxel is an approved chemotherapy drug, and SX-682 is a drug that aims to improve the immune system's ability to fight cancer. The study will first determine the best dose of SX-682 to use with docetaxel. Then, it will look at how well this combination shrinks tumors in participants. You may be able to join if you are 18 or older and have one of these cancers. The study plans to enroll 120 people, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It will determine the best dose of SX-682 and then evaluate its effectiveness when combined with docetaxel.
- What's involved
- Participants will take SX-682 by mouth twice a day and receive docetaxel through an IV over about 60 minutes. You will have assessments at baseline, during treatment cycles, and every three months until your cancer progresses or for up to two years after starting treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your tumor response will be assessed at baseline, during treatment cycles, and every three months until your cancer progresses or for up to two years after starting study treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07667400
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Not Yet Recruiting
PHASE1Ages 18+InterventionalTreatmentNational Cancer Institute (NCI)Government-funded
~120 participants
Updated 2026-08-31 on ClinicalTrials.gov
What's tested:SX-682DTX
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase I: To determine the RP2D of SX-682 in combination with DTX in participants with HNSCC, SGC, or mCRPC
Measured over 28 days
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Charalampos Floudas, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age \>= 18 years.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<= 2
Participants must have adequate organ and marrow function as defined below:
ANC \>= 1,500/mcL
Hemoglobin (Hgb) \>= 9 g/dL
Platelets (PLTs) \>= 100,000/mcL
Creatinine clearance \>= 50 mL/min (by Cockroft-Gault formula)
Total bilirubin \<= 1.5 x iULN (\<= 3 x ULN in participants with known/suspected Gilbert s disease)
ALT/AST \<= 2.5 x iULN
Activated partial thromboplastin time (aPTT) \<= 1.5 x iULN
Contraception as follows:
Women of child-bearing potential (WOCBP) must agree to use an effective method of contraception (barrier, hormonal, intrauterine device \[IUD\], surgical sterilization, abstinence) prior to study entry, for the duration of study treatment, and for up to 2 months after discontinuation of the study drugs. A participant may request a male partner to use an effective form of contraception to fulfill this requirement.
Men able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 4 months after discontinuation of the study drugs. A participant may request a female partner to use an effective form of contraception to fulfill this requirement. Men able to father a child must not freeze or donate sperm within the same period.
Nursing participants must be willing to discontinue nursing from study treatment initiation through one week after the last dose of study drugs.
Participants must be able to swallow oral medications.
Human immunodeficiency virus (HIV)-infected participants must have undetectable viral load (VL) and be on effective anti-retroviral therapy within 4 weeks prior to the study treatment initiation and have no history of opportunistic infections or Castleman s disease within 12 months prior to the study treatment initiation.
Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV VL.
Participants with evidence of chronic hepatitis C virus (HCV) infection must have undetectable HCV VL.
Participants must be able to understand and willing to sign a written informed consent document.
Histologically confirmed HNSCC (including oral cavity, oropharynx, larynx, hypopharynx, paranasal sinuses, nasopharynx) or SGC (including ACC and non-ACC) and recurrent/metastatic (R/M) or advanced incurable disease.
Prior treatment as follows:
Participants with R/M HNSCC must have prior systemic treatment (platinum-based chemotherapy and/or anti-PD(L)1 treatment).
Participants with R/M SGC may have any number of prior systemic treatment lines; prior systemic treatment not required for participation.
Participants must not have received systemic anticancer treatment within 3 weeks prior to first treatment administration. Note: Treatment-related toxicities must have resolved to Grade \<2 or be minimal and not constitute a safety risk. Participants with SGC previously treated with hormonal therapies (e.g., drugs targeting the androgen receptor) may continue these drugs concomitantly with study therapy. Participants with bone metastases or hypercalcemia on intravenous bisphosphonate medications, denosumab, or similar agents, are eligible to participate and may continue this treatment.
Presence of \>= 1 measurable lesion by RECIST v 1.1 criteria.
Documented histopathological confirmation of prostate cancer. If no pathologic report or specimen is available, participants may enroll with a history of clinical course consistent with the disease.
Participants must have mCRPC, defined as at least one lesion on TC-99 bone scan or at least one lesion that is measurable per RECIST 1.1.
Participants must need ADT as part of their cancer therapy (unless previous orchiectomy)
Castrate testosterone level (\<50 ng/dl or 1.7 nmol/L)
Prior treatment as follows:
DTX for mCRPC is allowed but participants must not have had progression while on docetaxel or within 3 months after completing DTX for mCRPC
Participants must have been previously treated with modern anti-androgens such as abiraterone, enzalutamide, apalutamide, or darolutamide.
Progression defined as two consecutive rising PSA values at least 1 week apart or radiographic evidence of progression seen on computed tomography (CT) scan or TC- 99 bone scan.
Toxicities related to prior therapy, including surgery and/or radiation, must have resolved to \< Grade 1 per CTCAE v.6.0.
Exclusion
History of allergic reactions attributed to compounds of similar chemical or biologic composition to DTX, SX-682, or other agents used in study (e.g., polysorbate 80).
Known active brain metastases. Note: Participants with previously treated brain metastases are eligible if imaging at least four weeks prior to first trial treatment shows no evidence of progression and neurologic symptoms have resolved, have no new or enlarging brain metastases, and are not using glucocorticoids for at least a week prior to first trial treatment
Participants must not have received other investigational agents within 3 weeks prior to the first dose of the study drug(s).
Participants must not have received major surgery within 14 days prior to the first drug administration (minimally invasive procedures such as diagnostic biopsies are permitted). If participant underwent major surgery, they must have recovered adequately (according to the Principal Investigator) from the toxicity and/or complications from the intervention prior to starting study treatment.
Treatment (systemic) with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 (CYP3A4) listed at https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-druginteractions- table-substrates-inhibitors-and-inducers#table2-2,table3-3,table5-2 within 2 weeks or 5 half-lives (whichever is shorter) prior to the start of the study treatment.
Prior or concurrent malignancy whose natural history or treatment has potential to interfere with the safety or efficacy assessment of the study treatment.
Participants with serious uncontrolled intercurrent illness evaluated by medical history, electrocardiogram (EKG), and physical exam that would unacceptably increase risk for the participant or impair the ability to evaluate the endpoints of the study or that would limit compliance with study requirements.
Participants must not have received large-field radiotherapy within 2 weeks prior to first treatment administration. All residual treatment-related toxicities must have resolved to Grade \<2 (except for radiation-induced xerostomia/dysgeusia) or be minimal and not constitute a safety risk.
Positive pregnancy serum or urine beta-human chorionic gonadotropin (beta-hCG) test
Use of other medications for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g., phytoestrogens and saw palmetto) within 1 week prior to the study treatment initiation.
Cancer related neuropathy at screening
Baseline QTcF \>= 470 ms
What this trial measures
- Phase I: To determine the RP2D of SX-682 in combination with DTX in participants with HNSCC, SGC, or mCRPC28 days
Toxicities will be tabulated and reported according to grade and type of toxicity experienced. Responses will be reported as the proportion of evaluable participants along with a confidence interval.
- Phase II: To determine the efficacy of the combination of SX-682 and DTX in participants with HNSCC or SGC using ORR per RECIST v 1.1 or with mCRPC using RECIST v1.1 and Prostate Cancer Working Group 3Assessment at baseline, C4D8, 7 days after C6, and then every 3 months until PD or until 2 years after study treatment initiation
Overall response rate (ORR) as defined by the proportion of participants who achieve a response (CR+PR) will be reported separately for each, along with 95% and 80% confidence intervals (Clopper-Pearson).